MCL1 and AL amyloidosis: Among them, the widely studied MCL-1 inhibitors are BH3-mimics, including AZD5991, S63845, MIM1, etc. (Tron et al., 2018; Mallick et al., 2019; Moujalled et al., 2019; Wei et al., 2020), which have good effects on hematological tumors and multiple myeloma and have made great progress in combination with established therapies (Caenepeel et al., 2018).